Literature DB >> 15655681

[Chronic bronchitis, COPD].

H R Wirtz1.   

Abstract

Chronic bronchitis is part and precursor of COPD, a complex disease triggered mostly by exposure to cigarette smoke. However COPD develops only in patients with specific susceptibility probably determined by genetic factors or additional risk factors. A specific type of inflammation resides in the bronchial and bronchiolar walls, that infers damage not only to airway structure but also to surrounding alveolar attachments and thus to the lung parenchyma. Chronic bronchitis, fibrosing bronchiolitis and emphysema constitute the three main stems of pathology of the disease but may coexist with varying extent. The clinical picture is therefore quite variable. Treatment exists largely in bronchodilation combining different mechanisms and using long acting drugs usually applied by inhalation. Acute exacerbations promote progression of the disease, which must be counteracted by adaptation and intensification of therapy, in some cases including non invasive or invasive ventilation. Several non-pharmacologic measures such as smoking cessation, rehabilitation, nutritional support, long term oxygen therapy, lung volume reduction and possibly lung transplantation may be available for appropriate patients and have to be considered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15655681     DOI: 10.1007/s00108-004-1335-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  31 in total

1.  Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation.

Authors:  M Saetta; G Turato; S Baraldo; A Zanin; F Braccioni; C E Mapp; P Maestrelli; G Cavallesco; A Papi; L M Fabbri
Journal:  Am J Respir Crit Care Med       Date:  2000-03       Impact factor: 21.405

Review 2.  [Guidelines for the diagnosis and treatment chronic obstructive bronchitis and pulmonary emphysema issued by Deutsche Atemwegsliga and Deutsche Gesellschaft für pneumologie].

Authors:  H Worth; R Buhl; U Cegla; C P Criée; A Gillissen; P Kardos; D Köhler; H Magnussen; R Meister; D Nowak; W Petro; K F Rabe; G Schultze-Werninghaus; H Sitter; H Teschler; T Welte; R Wettengel
Journal:  Pneumologie       Date:  2002-11

Review 3.  Treatment of stable chronic obstructive pulmonary disease.

Authors:  Stephen I Rennard
Journal:  Lancet       Date:  2004 Aug 28-Sep 3       Impact factor: 79.321

4.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

5.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial.

Authors:  J Vestbo; T Sørensen; P Lange; A Brix; P Torre; K Viskum
Journal:  Lancet       Date:  1999-05-29       Impact factor: 79.321

6.  Quantitative relationships between cigarette smoking and ventilatory function.

Authors:  B Burrows; R J Knudson; M G Cline; M D Lebowitz
Journal:  Am Rev Respir Dis       Date:  1977-02

7.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.

Authors:  Robert Wise; John Connett; Gail Weinmann; Paul Scanlon; Melissa Skeans
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

8.  Epidermal growth factor system regulates mucin production in airways.

Authors:  K Takeyama; K Dabbagh; H M Lee; C Agustí; J A Lausier; I F Ueki; K M Grattan; J A Nadel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

9.  Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease.

Authors:  A M Schols; J Slangen; L Volovics; E F Wouters
Journal:  Am J Respir Crit Care Med       Date:  1998-06       Impact factor: 21.405

10.  Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

Authors:  D E O'Donnell; T Flüge; F Gerken; A Hamilton; K Webb; B Aguilaniu; B Make; H Magnussen
Journal:  Eur Respir J       Date:  2004-06       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.